Publications by authors named "Xiayang Ren"

Claim this Profile
C
Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
Yinjing Hou, Xiayang Ren, Ying Chen, Yanfeng Wang

Expert Opin Drug Saf· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions.
Xiayang Ren, Lei Deng, Xin Dong, Ying Bai, Guohui Li

Int J Immunopathol Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system database.
Xiayang Ren, Ping Sun, Yanfeng Wang

Expert Opin Drug Saf· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system.
Yuheng Chen, Xiayang Ren, Yuanyuan Dai, Yanfeng Wang

Sci Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions.
Xiayang Ren, Lu Li, Yiran Chen, Xiangli Cui, Rui Wan

BMC Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Xiayang Ren, Haijun Wang, Lei Deng, Wenqing Wang, Yanfeng Wang

Int Immunopharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Xiayang Ren, Guanmin Zhang, Guohui Li, Yanfeng Wang

BMC Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
Yanfeng Wang, Chanjuan Cui, Lei Deng, Lin Wang, Xiayang Ren

Front Immunol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on FAERS databases.
Chanjuan Cui, Siyu Zhang, Xiayang Ren, Wei Cui, Yanfeng Wang

Eur J Pharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haematopoietic cytopenia associated with cyclin-dependent kinase 4/6 inhibitors: A real-world study of data from the food and drug administration adverse event reporting system database.
Xiayang Ren, Cilin Yan, Le Tian, Xiangli Cui

Int J Immunopathol Pharmacol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular toxicity associated with angiogenesis inhibitors: A comprehensive pharmacovigilance analysis based on the FDA Adverse Event Reporting System database from 2014 to 2021.
YanFeng Wang, Chanjuan Cui, Xiayang Ren, Xinran Dong, Wei Cui

Front Cardiovasc Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database.
Chanjuan Cui, Lei Deng, Wenqing Wang, Xiayang Ren, Yanfeng Wang

Front Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the Practice of Pharmaceutical Care for Cancer Pain Management in Outpatient Clinics Using the Delphi Method.
Lu Zhang, Xia-Yang Ren, Hang-Xing Huang, Ya-Min Huang, Ling Huang

Front Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis